Table 3. Univariate analysis for EFS and OS in advanced disease (stages II and III, n = 68).
| EFS | OS | ||||||
|---|---|---|---|---|---|---|---|
| Variables | Number | HR | 95% CI | p | HR | 95% CI | p |
| Site of primary | Testicular (n = 60) | 1 | 0.94 | 1 | 0.59 | ||
| Retroperitoneum (n = 8) | 2.03 | 0.46–8.94 | 1.74 | 0.22–13.45 | |||
| Age | ≤28 years (n = 35) | 1 | 0.06 | 1 | 0.07 | ||
| >28 years (n = 33) | 0.39 | 0.15–1.03 | 0.35 | 0.11–1.09 | |||
| Symptom durationa | ≤4 months (n = 27) | 1 | 0.63 | 1 | 0.7 | ||
| >4 months (n = 24) | 0.76 | 0.25–2.28 | 1.25 | 0.38–4.13 | |||
| Testicular violation | No (n = 49) | 1 | 0.39 | 1 | 0.02 | ||
| Yes (n = 11) | 1.66 | 0.57–5.21 | 4.24 | 1.26–14.27 | |||
| Type of orchiectomyb | High inguinal (n = 50) | 1 | 0.24 | 1 | 0.32 | ||
| Scrotal (n = 9) | 1.96 | 0.64–6.02 | 1.92 | 0.53–6.98 | |||
| Stage of disease | Stage II (n = 19) | 1 | 0.19 | 1 | 0.21 | ||
| Stage III (n = 49) | 2.26 | 0.66–7.34 | 2.59 | 0.58–11.55 | |||
| IGCCCG risk groupc | Good (n = 29) | 1 | 1 | ||||
| Intermediate (n = 13) | 3.09 | 0.98–9.75 | 0.06 | 1.83 | 0.45–7.39 | 0.4 | |
| Poor (n = 21) | 2.64 | 0.83–8.36 | 0.1 | 2.87 | 0.81–10.3 | 0.1 | |
| S3 marker (n = 60) | No (n = 49) | 1 | 0.18 | 1 | 0.04 | ||
| Yes (n = 11) | 2.20 | 0.70–6.92 | 3.74 | 1.07–13.04 | |||
| Non-pulmonary visceral mets | Absent (n = 55) | 1 | 0.09 | 1 | 0.08 | ||
| Present (n = 13) | 2.32 | 0.89–6.07 | 2.59 | 0.88–7.64 | |||
| Chemotherapy typed | BEP (n = 43) | 1 | 0.07 | 1 | 0.07 | ||
| EP (n = 21) | 0.32 | 0.09–1.08 | 0.15 | 0.02–1.28 | |||
a
Symptom duration not recorded in 17 patients
b
One patient did not undergo orchiectomy
c
Risk stratification not available in five patients
d
Two patients received VIP based chemotherapy and another two patients underwent RPLND
BEP, Bleomycin/etoposide/cisplatin; CI, Confidence interval; EFS, Event free survival; EP, Etoposide/cisplatin; HR, Hazard ratio, IGCCCG, International Germ Cell Cancer Collaborative Group; OS, Overall survival